Calculators, Algorithms, Drug Interaction CheckersTools
Back To Search Results

Perioperative Cardiac Management

Author: Hector A. Bonaccorsi Editor: Bracken Burns Updated: 4/17/2023 4:35:01 PM

Introduction

The importance of the appropriate perioperative cardiac management in non-cardiac surgery lies in the high number of surgical procedures performed each year and the related cardiac complications, which account for almost half of the perioperative morbidity.[1] The risk of complications in non-cardiac surgery depends on (1) the type, urgency, and duration of the surgery and (2) the patient risk factors, including the perioperative condition and comorbidities. Perioperative cardiac management is a process of risk stratification and mitigation and not "cardiac clearance" as is often requested by providers.

Issues of Concern

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Issues of Concern

Type of Surgery

Regarding cardiac risk, surgical and endovascular procedures may be classified into three categories according to the estimated 30-day cardiac event rates (cardiac death and myocardial infarction) without considering the patient's comorbidities:[2]

Low-Risk (Less Than 1%)

  • Dermatological
  • Dental
  • Ophthalmologic
  • Vascular: carotid artery stenting and carotid endarterectomy in asymptomatic patients
  • Urological: minor surgery, transurethral resection of the prostate
  • Gynecological: minor surgery, breast surgery
  • Orthopedic: minor surgery (e.g., meniscectomy)
  • Reconstructive surgery
  • Thyroid surgery

Intermediate-Risk (between 1% to 5%)

  • Abdominal: cholecystectomy, hiatal hernia repair, splenectomy
  • Vascular: carotid artery stenting and carotid endarterectomy in symptomatic patients, peripheral artery angioplasty, endovascular aneurysm repair
  • Urological: major surgery including renal transplantation
  • Gynecological: major surgery
  • Neurological: major surgery (spine)
  • Orthopedic: major surgery (hip)
  • Head and neck surgery

High-Risk (Over 5%)

  • Vascular: aortic surgery, lower limb revascularization or amputation, thromboembolectomy
  • Thoracic: esophagectomy, pneumonectomy, lung transplantation
  • Abdominal: repair of a perforated bowel, pancreatic surgery, bile duct surgery, liver resection, liver transplantation.
  • Urological: total cystectomy
  • Adrenal resection

It is worth noting that procedures involving a laparoscopic approach may be associated with cardiovascular complications, so these patients should undergo a preoperative risk assessment.[3]

Evaluation of Patient-Related Risk Factors

The preoperative cardiac evaluation must be tailored to each particular patient, surgical type, and urgency. History-taking and examination as a first step, including the assessment of functional capacity and risk indices, will allow the practitioner to determine the extent of preoperative cardiac evaluation. Bear in mind that ancillary exams should only be requested if the results would influence patient management. Most "low perioperative cardiac risk" patients can undergo low- and intermediate-risk surgery with only a clinical assessment.

Functional Capacity

  • The evaluation of functional capacity is an important item in the preoperative cardiac risk assessment and is measured given the daily activities or, more objectively, in metabolic equivalents (METs). One MET corresponds to the basal metabolic rate of an average adult.
  • The inability to climb 2 flights of stairs or run a short distance (less than 4 METs) shows the low functional capacity and may predict survival after lung resection and complications after major non-cardiac surgery.[4] Conversely, when functional capacity is high, the prognosis is promising, even in a patient with stable ischemic heart disease or risk factors.[5] Most highly functional asymptomatic patients do not require further cardiovascular testing.

Calculation of Surgical Risk

A validated risk-prediction tool can predict the risk of perioperative major adverse cardiac events (MACE) in patients undergoing non-cardiac surgery.[3][6] Current risk prediction tools used include:

  • Revised Cardiac Risk Index (RCRI) or the Lee risk index is the most used. It was designed in 1999 to predict myocardial infarction, pulmonary edema, ventricular fibrillation or cardiac arrest, and complete atrioventricular block. It operates with six risk factors: surgical type, ischemic heart disease history, heart failure history, cerebrovascular disease history, preoperative therapy with insulin, and creatinine greater than 170 mmol/L (greater than 2 mg/dl).[7]
  • American College of Surgeon's tool predicts risk for myocardial infarction and cardiac arrest. Its development was based on data from 2007, and it identified five predictors: type of surgery, functional status, elevated creatinine (greater than 130 mmol/L or greater than 1.5 mg/dl), the American Society of Anesthesiologists (ASA) class, and the age.  It seems to have a better performance than the Lee index but does not predict some significant complications such as pulmonary edema and complete heart block.[8]
  • The most recent surgical risk calculator developed by The American College of Surgeons was introduced in 2013 and is available online. It predicts complications and perioperative death and requires the typing of a high number of risk factors to be calculated, including 21 patient specifics.[9]

Biomarkers

Several studies have examined the potential utility of including biomarkers to improve the prediction of preoperative risk. The following are the most used biomarkers:

  • Cardiac troponins T and I for myocardial ischemia and damage
  • C-reactive protein for inflammation
  • B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) for ventricular function

The existing preliminary evidence shows that the increase in troponin T in the perioperative period reflects clinically significant myocardial damage associated with poor cardiac prognosis and surgical outcomes.[1][10] Some studies have shown that high preoperative BNP and NT-proBNP values have independent prognostic significance to predict cardiac events and long-term mortality after non-cardiac vascular surgery.[11][12] Thus, with the current evidence, the preoperative assessment via biomarkers for patients undergoing non-cardiac surgery cannot be recommended for screening in all patients, but these can be considered for high-risk patients (functional capacity less than 4 METs or with an RCRI value greater than 1 for vascular surgery and greater than 2 for non-vascular surgery).

Non-Invasive and Invasive Testing

Myocardial ischemia, valvular heart disease, and ventricular dysfunction are known major determinants of surgical risk. Preoperative non-invasive and invasive testing may be helpful for diagnosis in patients with strong clinical suspicion or improve the condition in patients with known cardiac diseases. The investigation should be carried out as in patients who will not undergo surgery and should only be undertaken if the expected outcome would change perioperative management or help inform the patient about their options.

Risk-Reduction Strategies: Perioperative Medical Therapy

Beta-Blockers

The evidence currently available shows that the preoperative use of beta-blockers was associated with a reduction in cardiac events but not in surgical death.[13] In addition, preoperative use was associated with arterial hypotension, bradycardia, and stroke.[14][15] Therefore, the following recommendations are made:[3][6]

  • Patients undergoing surgery who have been on beta-blockers chronically should continue use. It should be noted that in a national cohort study, patients with uncomplicated arterial hypertension that received 2 drugs until surgery, including a beta-blocker, suffered higher cardiac mortality, infarction, and stroke rate.[16]
  • In patients with an intermediate or high risk of developing myocardial ischemia or with 3 or more RCRI risk factors, it may be reasonable, to begin with beta-blockers in the preoperative period. Atenolol or bisoprolol should be considered as a first-choice drug.[17][18]
  • Regardless of whether the patient was previously using beta-blockers, administration after surgery may be justified due to clinical needs.
  • In patients with obstructive pulmonary disease who need it, cardioselective beta-blocker therapy is not contraindicated.[19][20]

Perioperative Statin Therapy

Statins, in addition to their effect on lipids, induce coronary plaque stabilization through pleiotropic effects. This may prevent plaque rupture and subsequent myocardial infarction in the perioperative period. Preliminary evidence supports that preoperative statin use in non-cardiac surgery may decrease mortality and myocardial injury.[21] Besides, some studies have shown that the preoperative statin therapy interruption in a patient within 2 years following stent placement or immediately after aortic surgery may increase the mortality and myocardial injury, respectively.[22][23] Therefore, the following recommendations are made[3][6]:

  • The patients that will undergo surgery who have been on statins chronically should continue their use.
  • Preoperative initiation of statin use may be reasonable in patients undergoing vascular surgery and patients with clinical indications who are undergoing high-risk procedures.
  • If statins are being used during the perioperative period, long half-life or extended-release formulations should be administered preoperatively since there are no parenteral formulations to use immediately after surgery.
  • Ideally, preoperative therapy with the statin should begin at least two weeks before surgery to detect any adverse effects of the drug before surgery.

Calcium Channel Blockers

Further evidence is needed to define the value of these drugs during the perioperative period of non-cardiac surgery. Calcium channel blockers should be continued during the perioperative period in patients with vasospastic angina.[3] Heart rate-reducing calcium channel blockers may be considered in patients with beta-blockers adverse effects unless they have a contraindication.[3]

Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Receptor Blockers (ARBs)

Currently, there is no significant evidence showing the benefit of continuing the administration of ACEIs or ARBs to patients who will undergo non-cardiac surgery.[24] The perioperative use of ACEIs or ARBs increases the arterial hypotension risk, and a recent cohort study showed that withdrawal before surgery reduced mortality, stroke, and myocardial injury.[25][26] Therefore, whether the preoperative use of these drugs should be continued or discontinued remains debatable until more evidence is available. If discontinued, the morning before surgery is sufficient time, and it could be resumed after surgery as soon as blood volume and pressure are stable.

Antiplatelet Agents

In patients with coronary stents or those who have suffered acute coronary syndrome (ACS), the early discontinuation of double antiplatelet therapy (DAPT) significantly increases the risk of thrombosis, and therefore, acute coronary events.[27] In patients with a known cardiovascular disease or a high risk of developing it, even if they do not have coronary stents, the withdrawal of antiplatelet therapy may be associated with the appearance of new cardiac events.[28][29][30] On the other hand, the risk of perioperative bleeding is greater in patients who continue to receive aspirin and even higher with DAPT.[6][31] Therefore, the following recommendations are made:

  • If possible, in patients with coronary stent placement without ACS within the last year, the surgery should be rescheduled, so they receive DAPT during six weeks for the bare-metal stent and at least 4 months, or ideally 6 months, for the drug-eluting stent. Afterward, P2Y-inhibitor should be discontinued for a week, and if feasible, all patients should continue with aspirin and resume DAPT as soon as possible after surgery.[32]
  • Elective surgery should be delayed for at least 12 months in patients who suffered an ACS, and the DAPT should be continued throughout that period, regardless of ACS therapy used. Afterward, P2Y-inhibitor should be discontinued for one week, and if feasible, all patients should continue with aspirin and resume DAPT as soon as possible after surgery.[32]
  • In the cases mentioned above, whenever the surgery cannot be rescheduled, DAPT should be continued through the perioperative period unless the complications of risk due to bleeding outweighs the risk of a major cardiac adverse event (e.g., major, active, life-threatening bleeding; intracranial, spinal or posterior chamber of the eye surgery).[32]
  • Initiation of aspirin therapy within 4 hours of non-cardiac surgery and continuation during the perioperative period in patients who do not receive aspirin, with previous coronary stent placement (more than 6 weeks for bare-metal and more than one year for drug-eluting) seems to reduce the risk of death and myocardial infarction but increases the risk of bleeding.[33]
  • Discontinuation of aspirin for at least 1 week before a procedure is recommended in patients without cardiovascular disease to undergo elective non-cardiac surgery unless the risk of cardiac events outweighs the risk of bleeding.[34]
  • Initiation or continuation of aspirin therapy may be reasonable in patients with cardiovascular disease who have not had coronary stent placement but have an elevated risk of cardiac events unless the type of surgery they will undergo has a significant increase in severe complications due to the increased risk of bleeding (e.g., intracranial surgery, spinal surgery, transurethral prostatectomy).[3][6][28][29][30]
  • For patients who need interruption of antiplatelet therapy, it should be 5 days before the surgery for clopidogrel or ticagrelor and 7 days for aspirin and prasugrel. Avoid the use of low-molecular-weight heparin for bridging in these patients.[3]

Anticoagulants

Thromboembolic risk and the risk of bleeding relative to the type of surgery to be performed should be weighed in each patient treated with anticoagulants. In high thromboembolic risk cases with a low risk of surgical bleeding (e.g., skin surgery), anticoagulant therapy may not be discontinued. In surgeries with a high risk of bleeding, anticoagulant therapy should be discontinued. In these cases, if there is a patient with a high risk of thromboembolic complications, the anticoagulants should be dosed so that the effect remains only until a few hours before surgery.

Risk-Reduction Strategies: Preoperative Cardiac Surgery and Endovascular Procedures

Coronary Revascularization[3][6]

Indications for surgical or endovascular coronary revascularization in the preoperative period of a non-cardiac surgery are like those in the non-surgical setting. Control of myocardial ischemia before non-cardiac surgery is recommended whenever the operation can be delayed at no risk for the patient. Routine myocardial revascularization in patients without myocardial ischemia is not recommended before non-cardiac surgery exclusively to reduce the risk of perioperative cardiac events.

Interventions on the Heart Valves[6][35]

Since the following valvular heart diseases increase the perioperative risk of cardiac events in non-cardiac surgery, it is reasonable to treat them in advance of non-cardiac surgery to reduce the risk whenever the level of severity mentioned below is reached.

  • Aortic stenosis: In patients with severe aortic stenosis, urgent non-cardiac surgery should be performed under careful hemodynamic monitoring. In symptomatic patients with severe aortic stenosis that need elective non-cardiac surgery, valve replacement should be considered first. In this group of patients, aortic balloon valvuloplasty or transcatheter aortic valve implantation may be considered in those at high risk for a valvular surgery, 
  • Mitral stenosis: Patients with severe mitral stenosis, symptomatic, or systolic pulmonary artery pressure greater than 50 mmHg should undergo valvular surgery or percutaneous mitral commissurotomy before non-cardiac surgery if it is a high-risk one.
  • Aortic and mitral regurgitation: In patients with severe mitral or aortic regurgitation, symptomatic or ventricular dysfunction, valvular surgery should be considered prior to non-cardiac surgery.

Clinical Significance

The clinical significance of the proper perioperative cardiac management in non-cardiac surgery lies in the high number of surgical procedures performed each year and the related cardiac complications. Before surgery, the health professional must assess the risk of surgery type and the patient's risk. The patient's risk can be specified through history, examination, and non-invasive and invasive tests. The evaluation of functional capacity and the calculation of surgical risk may be useful in this regard. The preventive approach is pivotal, and if the situation warrants it, risk reduction strategies should be implemented with drugs, surgery, or endovascular procedures.

In patients with true life-threatening surgical issues, operative intervention should not be delayed by ticagrelor or extensive perioperative cardiac management. In patients who continue antiplatelet agents or anticoagulants in the perioperative period, a meticulous surgical technique should be employed to minimize the risk of postoperative bleeding complications.

Enhancing Healthcare Team Outcomes

A primary care physician can often do the preoperative clinical evaluation. However, in patients with symptoms or a history of heart disease, who will undergo moderate or high-risk procedures, it will often be necessary to involve the cardiologist.

Before the surgery, the doctor frequently must request electrocardiograms, laboratory tests, stress tests, echocardiography, etc., so it is important to him to keep in touch with the technicians and physicians who do them to know their details.

The physician who performs perioperative cardiac management should communicate with the surgeon, the anesthesiologist, and the intensivist (if the patient requires intensive care) to achieve the best possible results.

Initiation of preoperative high-dose beta-blockers without titration (in other words, to be initiated on the day of surgery) is not safe.[36] [Level I] Ideally, preoperative beta-blockers should be initiated at least 1 week to 1 month before the surgery, be titrated to a resting heart rate of 55 to 70 beats per minute, and be continued for at least 1 month postoperatively.[6]

Management of perioperative antiplatelet therapy should be determined by a consensus of the interprofessional team, including the surgeon, anesthesiologist, cardiologist, and patient.[32]

References

[1]

Vascular Events In Noncardiac Surgery Patients Cohort Evaluation (VISION) Study Investigators, Devereaux PJ, Chan MT, Alonso-Coello P, Walsh M, Berwanger O, Villar JC, Wang CY, Garutti RI, Jacka MJ, Sigamani A, Srinathan S, Biccard BM, Chow CK, Abraham V, Tiboni M, Pettit S, Szczeklik W, Lurati Buse G, Botto F, Guyatt G, Heels-Ansdell D, Sessler DI, Thorlund K, Garg AX, Mrkobrada M, Thomas S, Rodseth RN, Pearse RM, Thabane L, McQueen MJ, VanHelder T, Bhandari M, Bosch J, Kurz A, Polanczyk C, Malaga G, Nagele P, Le Manach Y, Leuwer M, Yusuf S. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA. 2012 Jun 6:307(21):2295-304. doi: 10.1001/jama.2012.5502. Epub     [PubMed PMID: 22706835]

[2]

Glance LG, Lustik SJ, Hannan EL, Osler TM, Mukamel DB, Qian F, Dick AW. The Surgical Mortality Probability Model: derivation and validation of a simple risk prediction rule for noncardiac surgery. Annals of surgery. 2012 Apr:255(4):696-702. doi: 10.1097/SLA.0b013e31824b45af. Epub     [PubMed PMID: 22418007]

Level 2 (mid-level) evidence

[3]

Kristensen SD, Knuuti J, Saraste A, Anker S, Bøtker HE, Hert SD, Ford I, Gonzalez-Juanatey JR, Gorenek B, Heyndrickx GR, Hoeft A, Huber K, Iung B, Kjeldsen KP, Longrois D, Lüscher TF, Pierard L, Pocock S, Price S, Roffi M, Sirnes PA, Sousa-Uva M, Voudris V, Funck-Brentano C, Authors/Task Force Members. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). European heart journal. 2014 Sep 14:35(35):2383-431. doi: 10.1093/eurheartj/ehu282. Epub 2014 Aug 1     [PubMed PMID: 25086026]

[4]

Biccard BM. Relationship between the inability to climb two flights of stairs and outcome after major non-cardiac surgery: implications for the pre-operative assessment of functional capacity. Anaesthesia. 2005 Jun:60(6):588-93     [PubMed PMID: 15918830]

[5]

Morris CK, Ueshima K, Kawaguchi T, Hideg A, Froelicher VF. The prognostic value of exercise capacity: a review of the literature. American heart journal. 1991 Nov:122(5):1423-31     [PubMed PMID: 1951007]

Level 2 (mid-level) evidence

[6]

Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, Davila-Roman VG, Gerhard-Herman MD, Holly TA, Kane GC, Marine JE, Nelson MT, Spencer CC, Thompson A, Ting HH, Uretsky BF, Wijeysundera DN, American College of Cardiology, American Heart Association. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Journal of the American College of Cardiology. 2014 Dec 9:64(22):e77-137. doi: 10.1016/j.jacc.2014.07.944. Epub 2014 Aug 1     [PubMed PMID: 25091544]

Level 1 (high-level) evidence

[7]

Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, Sugarbaker DJ, Donaldson MC, Poss R, Ho KK, Ludwig LE, Pedan A, Goldman L. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999 Sep 7:100(10):1043-9     [PubMed PMID: 10477528]

Level 2 (mid-level) evidence

[8]

Gupta PK, Gupta H, Sundaram A, Kaushik M, Fang X, Miller WJ, Esterbrooks DJ, Hunter CB, Pipinos II, Johanning JM, Lynch TG, Forse RA, Mohiuddin SM, Mooss AN. Development and validation of a risk calculator for prediction of cardiac risk after surgery. Circulation. 2011 Jul 26:124(4):381-7. doi: 10.1161/CIRCULATIONAHA.110.015701. Epub 2011 Jul 5     [PubMed PMID: 21730309]

Level 1 (high-level) evidence

[9]

Cohen ME, Ko CY, Bilimoria KY, Zhou L, Huffman K, Wang X, Liu Y, Kraemer K, Meng X, Merkow R, Chow W, Matel B, Richards K, Hart AJ, Dimick JB, Hall BL. Optimizing ACS NSQIP modeling for evaluation of surgical quality and risk: patient risk adjustment, procedure mix adjustment, shrinkage adjustment, and surgical focus. Journal of the American College of Surgeons. 2013 Aug:217(2):336-46.e1. doi: 10.1016/j.jamcollsurg.2013.02.027. Epub 2013 Apr 28     [PubMed PMID: 23628227]

Level 2 (mid-level) evidence

[10]

Weber M, Luchner A, Seeberger M, Mueller C, Liebetrau C, Schlitt A, Apostolovic S, Jankovic R, Bankovic D, Jovic M, Mitrovic V, Nef H, Mollmann H, Hamm CW. Incremental value of high-sensitive troponin T in addition to the revised cardiac index for peri-operative risk stratification in non-cardiac surgery. European heart journal. 2013 Mar:34(11):853-62. doi: 10.1093/eurheartj/ehs445. Epub 2012 Dec 19     [PubMed PMID: 23257946]

[11]

Rodseth RN, Padayachee L, Biccard BM. A meta-analysis of the utility of pre-operative brain natriuretic peptide in predicting early and intermediate-term mortality and major adverse cardiac events in vascular surgical patients. Anaesthesia. 2008 Nov:63(11):1226-33. doi: 10.1111/j.1365-2044.2008.05574.x. Epub 2008 Jul 31     [PubMed PMID: 18673363]

Level 1 (high-level) evidence

[12]

Karthikeyan G, Moncur RA, Levine O, Heels-Ansdell D, Chan MT, Alonso-Coello P, Yusuf S, Sessler D, Villar JC, Berwanger O, McQueen M, Mathew A, Hill S, Gibson S, Berry C, Yeh HM, Devereaux PJ. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. Journal of the American College of Cardiology. 2009 Oct 20:54(17):1599-606. doi: 10.1016/j.jacc.2009.06.028. Epub     [PubMed PMID: 19833258]

Level 1 (high-level) evidence

[13]

Wan YD, Zhang SG, Sun TW, Kan QC, Wang LX. The effects of perioperative β-blockers on mortality in patients undergoing non-cardiac surgery in real world: a meta-analysis of cohort studies. International journal of cardiology. 2014 Oct 20:176(3):605-10. doi: 10.1016/j.ijcard.2014.07.073. Epub 2014 Aug 4     [PubMed PMID: 25156833]

Level 1 (high-level) evidence

[14]

Blessberger H, Kammler J, Domanovits H, Schlager O, Wildner B, Azar D, Schillinger M, Wiesbauer F, Steinwender C. Perioperative beta-blockers for preventing surgery-related mortality and morbidity. The Cochrane database of systematic reviews. 2014 Sep 18:(9):CD004476. doi: 10.1002/14651858.CD004476.pub2. Epub 2014 Sep 18     [PubMed PMID: 25233038]

Level 1 (high-level) evidence

[15]

Mostafaie K, Bedenis R, Harrington D. Beta-adrenergic blockers for perioperative cardiac risk reduction in people undergoing vascular surgery. The Cochrane database of systematic reviews. 2015 Jan 14:1():CD006342. doi: 10.1002/14651858.CD006342.pub2. Epub 2015 Jan 14     [PubMed PMID: 25879091]

Level 1 (high-level) evidence

[16]

Jørgensen ME, Hlatky MA, Køber L, Sanders RD, Torp-Pedersen C, Gislason GH, Jensen PF, Andersson C. β-Blocker-Associated Risks in Patients With Uncomplicated Hypertension Undergoing Noncardiac Surgery. JAMA internal medicine. 2015 Dec:175(12):1923-31. doi: 10.1001/jamainternmed.2015.5346. Epub     [PubMed PMID: 26436291]

[17]

Wallace AW, Au S, Cason BA. Perioperative β-blockade: atenolol is associated with reduced mortality when compared to metoprolol. Anesthesiology. 2011 Apr:114(4):824-36. doi: 10.1097/ALN.0b013e3182110e83. Epub     [PubMed PMID: 21372680]

[18]

Ashes C, Judelman S, Wijeysundera DN, Tait G, Mazer CD, Hare GM, Beattie WS. Selective β1-antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol: a single-center cohort study of 44,092 consecutive patients. Anesthesiology. 2013 Oct:119(4):777-87. doi: 10.1097/ALN.0b013e3182a17f12. Epub     [PubMed PMID: 23820187]

Level 2 (mid-level) evidence

[19]

Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. The Cochrane database of systematic reviews. 2005 Oct 19:2005(4):CD003566     [PubMed PMID: 16235327]

Level 1 (high-level) evidence

[20]

Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PloS one. 2014:9(11):e113048. doi: 10.1371/journal.pone.0113048. Epub 2014 Nov 26     [PubMed PMID: 25427000]

Level 1 (high-level) evidence

[21]

Berwanger O, Le Manach Y, Suzumura EA, Biccard B, Srinathan SK, Szczeklik W, Santo JA, Santucci E, Cavalcanti AB, Archbold RA, Devereaux PJ, VISION Investigators. Association between pre-operative statin use and major cardiovascular complications among patients undergoing non-cardiac surgery: the VISION study. European heart journal. 2016 Jan 7:37(2):177-85. doi: 10.1093/eurheartj/ehv456. Epub 2015 Sep 1     [PubMed PMID: 26330424]

[22]

Richman JS, Graham LA, DeRussy A, Maddox TM, Itani KMF, Hawn MT. Perioperative beta blockers and statins for noncardiac surgery patients with coronary stents. American journal of surgery. 2017 Aug:214(2):180-185. doi: 10.1016/j.amjsurg.2017.05.001. Epub 2017 May 31     [PubMed PMID: 28641862]

[23]

Le Manach Y, Godet G, Coriat P, Martinon C, Bertrand M, Fléron MH, Riou B. The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesthesia and analgesia. 2007 Jun:104(6):1326-33, table of contents     [PubMed PMID: 17513620]

[24]

Zou Z, Yuan HB, Yang B, Xu F, Chen XY, Liu GJ, Shi XY. Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults. The Cochrane database of systematic reviews. 2016 Jan 27:2016(1):CD009210. doi: 10.1002/14651858.CD009210.pub2. Epub 2016 Jan 27     [PubMed PMID: 26816003]

Level 1 (high-level) evidence

[25]

Vaquero Roncero LM, Sánchez Poveda D, Valdunciel García JJ, Sánchez Barrado ME, Calvo Vecino JM. Perioperative use of angiotensin-converting-enzyme inhibitors and angiotensin receptor antagonists. Journal of clinical anesthesia. 2017 Aug:40():91-98. doi: 10.1016/j.jclinane.2017.04.018. Epub     [PubMed PMID: 28625460]

[26]

Roshanov PS, Rochwerg B, Patel A, Salehian O, Duceppe E, Belley-Côté EP, Guyatt GH, Sessler DI, Le Manach Y, Borges FK, Tandon V, Worster A, Thompson A, Koshy M, Devereaux B, Spencer FA, Sanders RD, Sloan EN, Morley EE, Paul J, Raymer KE, Punthakee Z, Devereaux PJ. Withholding versus Continuing Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers before Noncardiac Surgery: An Analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort. Anesthesiology. 2017 Jan:126(1):16-27     [PubMed PMID: 27775997]

[27]

Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, Testa L, Sheiban I, Sangiorgi G. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. European heart journal. 2006 Nov:27(22):2667-74     [PubMed PMID: 17053008]

Level 1 (high-level) evidence

[28]

Oscarsson A, Gupta A, Fredrikson M, Järhult J, Nyström M, Pettersson E, Darvish B, Krook H, Swahn E, Eintrei C. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. British journal of anaesthesia. 2010 Mar:104(3):305-12. doi: 10.1093/bja/aeq003. Epub     [PubMed PMID: 20150346]

Level 1 (high-level) evidence

[29]

Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006 Jan 17:113(2):203-12     [PubMed PMID: 16401776]

[30]

Burger W, Chemnitius JM, Kneissl GD, Rücker G. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. Journal of internal medicine. 2005 May:257(5):399-414     [PubMed PMID: 15836656]

Level 1 (high-level) evidence

[31]

Siller-Matula JM, Petre A, Delle-Karth G, Huber K, Ay C, Lordkipanidzé M, De Caterina R, Kolh P, Mahla E, Gersh BJ. Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis. European heart journal. Acute cardiovascular care. 2017 Dec:6(8):753-770. doi: 10.1177/2048872615585516. Epub 2015 May 5     [PubMed PMID: 25943554]

Level 2 (mid-level) evidence

[32]

Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'Gara PT, Sabatine MS, Smith PK, Smith SC Jr. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016 Sep 6:134(10):e123-55. doi: 10.1161/CIR.0000000000000404. Epub 2016 Mar 29     [PubMed PMID: 27026020]

Level 1 (high-level) evidence

[33]

Graham MM, Sessler DI, Parlow JL, Biccard BM, Guyatt G, Leslie K, Chan MTV, Meyhoff CS, Xavier D, Sigamani A, Kumar PA, Mrkobrada M, Cook DJ, Tandon V, Alvarez-Garcia J, Villar JC, Painter TW, Landoni G, Fleischmann E, Lamy A, Whitlock R, Le Manach Y, Aphang-Lam M, Cata JP, Gao P, Terblanche NCS, Ramana PV, Jamieson KA, Bessissow A, Mendoza GR, Ramirez S, Diemunsch PA, Yusuf S, Devereaux PJ. Aspirin in Patients With Previous Percutaneous Coronary Intervention Undergoing Noncardiac Surgery. Annals of internal medicine. 2018 Feb 20:168(4):237-244. doi: 10.7326/M17-2341. Epub 2017 Nov 14     [PubMed PMID: 29132159]

[34]

Devereaux PJ, Mrkobrada M, Sessler DI, Leslie K, Alonso-Coello P, Kurz A, Villar JC, Sigamani A, Biccard BM, Meyhoff CS, Parlow JL, Guyatt G, Robinson A, Garg AX, Rodseth RN, Botto F, Lurati Buse G, Xavier D, Chan MT, Tiboni M, Cook D, Kumar PA, Forget P, Malaga G, Fleischmann E, Amir M, Eikelboom J, Mizera R, Torres D, Wang CY, VanHelder T, Paniagua P, Berwanger O, Srinathan S, Graham M, Pasin L, Le Manach Y, Gao P, Pogue J, Whitlock R, Lamy A, Kearon C, Baigent C, Chow C, Pettit S, Chrolavicius S, Yusuf S, POISE-2 Investigators. Aspirin in patients undergoing noncardiac surgery. The New England journal of medicine. 2014 Apr 17:370(16):1494-503. doi: 10.1056/NEJMoa1401105. Epub 2014 Mar 31     [PubMed PMID: 24679062]

Level 1 (high-level) evidence

[35]

Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, Rosenhek R, Sjögren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL, ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. European heart journal. 2017 Sep 21:38(36):2739-2791. doi: 10.1093/eurheartj/ehx391. Epub     [PubMed PMID: 28886619]

[36]

POISE Study Group, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, Xavier D, Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Málaga G, Avezum A, Chan M, Montori VM, Jacka M, Choi P. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (London, England). 2008 May 31:371(9627):1839-47. doi: 10.1016/S0140-6736(08)60601-7. Epub 2008 May 12     [PubMed PMID: 18479744]

Level 1 (high-level) evidence